PL2097381T3 - Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu - Google Patents

Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu

Info

Publication number: PL2097381T3
Authority: PL; Poland
Prior art keywords: fluorophenoxy; methylpyridine; carbamoyl; trifluoromethyl; chloro
Prior art date: 2006-10-11

Application number

PL07818583T

Other languages

English (en)

Inventor

Alfons Grunenberg

Juergen Stiehl

Katharina Tenbieg

Birgit Keil

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-11

Filing date

2007-09-29

Publication date

2013-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38972960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2097381(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-29 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2013-11-29 Publication of PL2097381T3 publication Critical patent/PL2097381T3/pl

Links

125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

PL07818583T 2006-10-11 2007-09-29 Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu PL2097381T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP06021296		2006-10-11
PCT/EP2007/008503 WO2008043446A1 (en)	2006-10-11	2007-09-29	4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate
EP07818583.2A EP2097381B1 (en)	2006-10-11	2007-09-29	4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate

Publications (1)

Publication Number	Publication Date
PL2097381T3 true PL2097381T3 (pl)	2013-11-29

Family

ID=38972960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07818583T PL2097381T3 (pl)	2006-10-11	2007-09-29	Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu

Country Status (37)

Country	Link
US (3)	US9957232B2 (pl)
EP (1)	EP2097381B1 (pl)
JP (1)	JP5346293B2 (pl)
KR (1)	KR101418623B1 (pl)
CN (1)	CN101547903B (pl)
AR (1)	AR062927A1 (pl)
AU (1)	AU2007306716B2 (pl)
BR (1)	BRPI0719828B1 (pl)
CA (1)	CA2666170C (pl)
CL (1)	CL2007002930A1 (pl)
CO (1)	CO6150132A2 (pl)
CR (1)	CR10663A (pl)
CY (1)	CY1114637T1 (pl)
DK (1)	DK2097381T3 (pl)
ES (1)	ES2427358T3 (pl)
GT (1)	GT200900057A (pl)
HN (1)	HN2009000499A (pl)
IL (1)	IL197369A (pl)
JO (1)	JO3021B1 (pl)
MA (1)	MA30878B1 (pl)
MX (1)	MX2009002642A (pl)
MY (1)	MY152595A (pl)
NZ (1)	NZ576153A (pl)
PA (1)	PA8750301A1 (pl)
PE (1)	PE20081459A1 (pl)
PL (1)	PL2097381T3 (pl)
PT (1)	PT2097381E (pl)
RU (1)	RU2466992C2 (pl)
SG (1)	SG175584A1 (pl)
SI (1)	SI2097381T1 (pl)
SV (1)	SV2009003187A (pl)
TN (1)	TN2009000072A1 (pl)
TW (1)	TWI428322B (pl)
UA (1)	UA95984C2 (pl)
UY (1)	UY30633A1 (pl)
WO (1)	WO2008043446A1 (pl)
ZA (1)	ZA200902469B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1636585B2 (en) *	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en)	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
DK1797038T3 (da) *	2004-09-29	2012-09-03	Bayer Pharma AG	Termodynamisk stabil form af bay 43-9006-tosylat
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2089363A1 (en) *	2006-11-14	2009-08-19	Bayer Schering Pharma Aktiengesellschaft	Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide
CA2675980C (en)	2007-01-19	2016-06-21	Bayer Healthcare Llc	Use of dast for treatment of cancers with acquired resistance to kit inhibitors
AR081060A1 (es) *	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2015201426B2 (en) *	2010-04-15	2016-07-07	Bayer Healthcare Llc	Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
CA2805874A1 (en)	2010-07-19	2012-01-26	Bayer Healthcare Llc	Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US9381177B2 (en)	2010-10-01	2016-07-05	Bayer Intellectual Property Gmbh	Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
KR20140048218A (ko) *	2011-06-28	2014-04-23	바이엘 헬스케어 엘엘씨	레고라페닙을 함유하는 국소 안과용 약학 조성물
AR092439A1 (es)	2012-09-06	2015-04-22	Bayer Healthcare Llc	Composicion farmaceutica recubierta que contiene regorafenib
EP2900269B1 (en)	2012-09-25	2018-08-01	Bayer Pharma Aktiengesellschaft	Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
UY35183A (es)	2012-12-21	2014-07-31	Bayer Healthcare Llc	Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015049698A2 (en) *	2013-10-04	2015-04-09	Hetero Research Foundation	Process for regorafenib
CN103923000A (zh) *	2014-01-29	2014-07-16	苏州晶云药物科技有限公司	几种新晶型及其制备方法
CN104829523B (zh) *	2014-04-30	2017-10-31	药源药物化学（上海）有限公司	瑞戈非尼盐及其晶型、制备方法
WO2016005874A1 (en)	2014-07-09	2016-01-14	Shilpa Medicare Limited	Process for the preparation of regorafenib and its crystalline forms
WO2016038590A1 (en)	2014-09-12	2016-03-17	Mylan Laboratories Ltd	Process for the preparation of crystalline form i of regorafenib
CN104546776B (zh) *	2015-02-10	2017-08-22	杭州朱养心药业有限公司	瑞戈非尼片剂药物组合物和制法
CN105985287B (zh) *	2015-02-13	2018-07-17	上海京新生物医药有限公司	一种瑞戈非尼新晶型
CN107118153A (zh) *	2016-02-25	2017-09-01	石药集团中奇制药技术（石家庄）有限公司	一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) *	2016-05-13	2019-03-26	浙江大学	一种瑞戈非尼与β-环糊精的包合物及其制备方法
CA3244313A1 (en)	2017-06-02	2025-06-13	Bayer Healthcare Llc	Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3861989A1 (en)	2020-02-07	2021-08-11	Bayer Aktiengesellschaft	Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en)	2020-02-14	2021-08-19	Bayer Aktiengesellschaft	Combination of regorafenib and msln-ttc for treating cancer
CN111995571B (zh) *	2020-08-07	2021-12-03	天津理工大学	一种瑞戈非尼与马来酸的共晶及其制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL6705789A (pl)	1967-03-08	1968-09-09
US4223153A (en)	1979-02-09	1980-09-16	Eli Lilly And Company	Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
US5023252A (en) *	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
NZ220764A (en) *	1986-07-02	1989-09-27	Shionogi & Co	Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4835180A (en) *	1986-10-02	1989-05-30	Sterling Drug Inc.	N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
CO4410190A1 (es)	1994-09-19	1997-01-09	Lilly Co Eli	3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) *	1994-09-19	1997-05-13	Eli Lilly And Company	Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
WO1997046526A1 (en) *	1996-06-07	1997-12-11	Eisai Co., Ltd.	Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
JP2001500878A (ja)	1996-09-23	2001-01-23	イーライ・リリー・アンド・カンパニー	オランザピン二水和物ｄ
US6187799B1 (en) *	1997-05-23	2001-02-13	Onyx Pharmaceuticals	Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) *	1997-05-23	2002-02-05	Bayer Corporation	Inhibition of p38 kinase activity by aryl ureas
US20070244120A1 (en) *	2000-08-18	2007-10-18	Jacques Dumas	Inhibition of raf kinase using substituted heterocyclic ureas
US7517880B2 (en) *	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) *	1997-12-22	2008-12-04	Jacques Dumas	Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7329670B1 (en) *	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20120046290A1 (en) *	1997-12-22	2012-02-23	Jacques Dumas	Inhibition of p38 kinase activity using substituted heterocyclic ureas
US20080269265A1 (en) *	1998-12-22	2008-10-30	Scott Miller	Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP1158985B1 (en) *	1999-01-13	2011-12-28	Bayer HealthCare LLC	OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7928239B2 (en) *	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) *	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) *	1999-01-13	2011-02-10	Bayer Corp	ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
EP1140840B1 (en) *	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN190389B (pl) *	1999-07-14	2003-07-26	Ranbaxy Lab Ltd
EP1248869A2 (en)	2000-01-07	2002-10-16	Transform Pharmaceuticals, Inc.	High-throughput formation, identification, and analysis of diverse solid-forms
US7235576B1 (en) *	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) *	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003047579A1 (en) *	2001-12-03	2003-06-12	Bayer Pharmaceuticals Corporation	Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20080108672A1 (en) *	2002-01-11	2008-05-08	Bernd Riedl	Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928277B1 (en) *	2002-02-11	2011-04-19	Cox Jr Henry Wilmore	Method for reducing contamination
SI1478358T1 (sl) *	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2003068229A1 (en) *	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ATE529406T1 (de) *	2002-02-11	2011-11-15	Bayer Healthcare Llc	Aryl-harnstoffe als kinase inhibitoren
EP1504047B1 (en) *	2002-05-03	2007-12-12	Janssen Pharmaceutica N.V.	Polymeric microemulsions
US7557129B2 (en) *	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) *	2003-07-23	2007-11-28	Bayer Pharmaceuticals Corporation	Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005040100A1 (en) *	2003-10-15	2005-05-06	Bayer Healthcare Ag	Tetrahydro-naphthalene and urea derivatives
TWI338004B (en)	2004-02-06	2011-03-01	Bristol Myers Squibb Co	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP2295426A1 (en) *	2004-04-30	2011-03-16	Bayer HealthCare, LLC	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
ATE395905T1 (de) *	2004-08-27	2008-06-15	Bayer Pharmaceuticals Corp	Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
MY191349A (en) *	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DK1797038T3 (da) *	2004-09-29	2012-09-03	Bayer Pharma AG	Termodynamisk stabil form af bay 43-9006-tosylat
EP1797037B1 (en)	2004-09-29	2014-12-17	Bayer HealthCare LLC	Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
ATE482693T1 (de) *	2005-03-07	2010-10-15	Bayer Schering Pharma Ag	Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
MX2007014726A (es)	2005-05-27	2008-02-14	Bayer Healthcare Ag	Tratamiento combinado que comprende un compuesto diarilurea y una pi3, akt cinasa o inhibidores mtor (rapamicina) para tratamiento de cancer.
CA2609387A1 (en) *	2005-05-27	2006-11-30	Bayer Healthcare Ag	Combination therapy comprising diaryl ureas for treating diseases
WO2007047955A2 (en) *	2005-10-21	2007-04-26	Bayer Healthcare Llc	Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20090215835A1 (en) *	2005-10-31	2009-08-27	Scott Wilhelm	Treatment of cancer with sorafenib
US8329408B2 (en) *	2005-10-31	2012-12-11	Bayer Healthcare Llc	Methods for prognosis and monitoring cancer therapy
JP2009513707A (ja) *	2005-10-31	2009-04-02	バイエルヘルスケアリミティドライアビリティカンパニー	ジアリールウレア及び併用剤
US20080311601A1 (en) *	2005-11-02	2008-12-18	Elting James J	Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
BRPI0618522A2 (pt) *	2005-11-10	2011-09-06	Bayer Healthcare Ag	diaril uréia para o tratamento de hipertensão pulmonar
ATE493986T1 (de) *	2005-11-10	2011-01-15	Bayer Schering Pharma Ag	Diarylharnstoffe zur behandlung von pulmonaler hypertonie
BRPI0618597A2 (pt) *	2005-11-14	2011-09-06	Bayer Healthcare Llc	métodos de predição e prognóstico de cáncer e método de monitoramento de terapia contra o cáncer
JP2009515978A (ja) *	2005-11-14	2009-04-16	バイエルヘルスケアエルエルシー	Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
US20110195110A1 (en) *	2005-12-01	2011-08-11	Roger Smith	Urea compounds useful in the treatment of cancer
CA2633417A1 (en) *	2005-12-15	2007-06-21	Bayer Healthcare Ag	Diaryl ureas for treating virus infections
US20090227637A1 (en) *	2005-12-15	2009-09-10	Olaf Weber	Diaryl ureas for treating virus infections
US20100129321A1 (en) *	2005-12-15	2010-05-27	Bayer Healthcare Llc	Diaryl urea for treating virus infections
WO2007075650A2 (en) *	2005-12-21	2007-07-05	Bayer Healthcare Ag	Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
EP2094268A2 (en) *	2006-05-26	2009-09-02	Bayer HealthCare, LLC	Drug combinations with substituted diaryl ureas for the treatment of cancer
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100063112A1 (en) *	2006-11-09	2010-03-11	Bayer Schering Pharma Aktiengesellschaft	Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2089363A1 (en) *	2006-11-14	2009-08-19	Bayer Schering Pharma Aktiengesellschaft	Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide
JP2010514692A (ja) *	2006-12-20	2010-05-06	バイエルヘルスケアリミティドライアビリティカンパニー	癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
AU2007336873A1 (en) *	2006-12-20	2008-07-03	Bayer Healthcare Llc	4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl) phenyl]-1H-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
JP2010516692A (ja) *	2007-01-19	2010-05-20	バイエル・ヘルスケア・エルエルシー	化学療法剤に対し抵抗性を有する癌の処置
CA2675980C (en) *	2007-01-19	2016-06-21	Bayer Healthcare Llc	Use of dast for treatment of cancers with acquired resistance to kit inhibitors
EP2231612A1 (en) *	2008-01-17	2010-09-29	Sicor, Inc.	Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
JP2011525503A (ja) *	2008-06-25	2011-09-22	バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト	心不全を処置するためのジアリールウレア
JP5439494B2 (ja) *	2008-10-21	2014-03-12	バイエルヘルスケアエルエルシー	肝細胞癌と関連するシグネチャ遺伝子の同定
CA2775296A1 (en) *	2009-09-24	2011-03-31	Ranbaxy Laboratories Limited	Polymorphs of sorafenib acid addition salts
WO2011058522A1 (en) *	2009-11-12	2011-05-19	Ranbaxy Laboratories Limited	Sorafenib ethylsulfonate salt, process for preparation and use
WO2011146725A1 (en)	2010-05-19	2011-11-24	Bayer Healthcare Llc	Biomarkers for a multikinase inhibitor
CA2805874A1 (en)	2010-07-19	2012-01-26	Bayer Healthcare Llc	Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

2007
- 2007-09-20 AR ARP070104168A patent/AR062927A1/es unknown
- 2007-09-29 ES ES07818583T patent/ES2427358T3/es active Active
- 2007-09-29 EP EP07818583.2A patent/EP2097381B1/en active Active
- 2007-09-29 JP JP2009531733A patent/JP5346293B2/ja active Active
- 2007-09-29 AU AU2007306716A patent/AU2007306716B2/en active Active
- 2007-09-29 NZ NZ576153A patent/NZ576153A/en unknown
- 2007-09-29 MX MX2009002642A patent/MX2009002642A/es active IP Right Grant
- 2007-09-29 KR KR1020097007422A patent/KR101418623B1/ko active Active
- 2007-09-29 WO PCT/EP2007/008503 patent/WO2008043446A1/en not_active Ceased
- 2007-09-29 SI SI200731313T patent/SI2097381T1/sl unknown
- 2007-09-29 US US12/444,974 patent/US9957232B2/en active Active
- 2007-09-29 CN CN200780037680.2A patent/CN101547903B/zh active Active
- 2007-09-29 BR BRPI0719828-0A patent/BRPI0719828B1/pt active IP Right Grant
- 2007-09-29 SG SG2011071990A patent/SG175584A1/en unknown
- 2007-09-29 PL PL07818583T patent/PL2097381T3/pl unknown
- 2007-09-29 MY MYPI20091350 patent/MY152595A/en unknown
- 2007-09-29 PT PT78185832T patent/PT2097381E/pt unknown
- 2007-09-29 CA CA2666170A patent/CA2666170C/en active Active
- 2007-09-29 UA UAA200904623A patent/UA95984C2/ru unknown
- 2007-09-29 DK DK07818583.2T patent/DK2097381T3/da active
- 2007-09-29 RU RU2009117388/04A patent/RU2466992C2/ru active
- 2007-10-07 JO JOP/2007/0423A patent/JO3021B1/ar active
- 2007-10-08 UY UY30633A patent/UY30633A1/es not_active Application Discontinuation
- 2007-10-09 TW TW096137745A patent/TWI428322B/zh active
- 2007-10-10 PA PA20078750301A patent/PA8750301A1/es unknown
- 2007-10-10 PE PE2007001368A patent/PE20081459A1/es not_active Application Discontinuation
- 2007-10-11 CL CL200702930A patent/CL2007002930A1/es unknown
2009
- 2009-02-27 TN TN2009000072A patent/TN2009000072A1/fr unknown
- 2009-03-03 IL IL197369A patent/IL197369A/en active IP Right Grant
- 2009-03-11 CO CO09025191A patent/CO6150132A2/es unknown
- 2009-03-12 GT GT200900057A patent/GT200900057A/es unknown
- 2009-03-13 SV SV2009003187A patent/SV2009003187A/es unknown
- 2009-03-13 CR CR10663A patent/CR10663A/es unknown
- 2009-03-18 HN HN2009000499A patent/HN2009000499A/es unknown
- 2009-04-09 ZA ZA200902469A patent/ZA200902469B/xx unknown
- 2009-05-08 MA MA31857A patent/MA30878B1/fr unknown
2013
- 2013-09-16 CY CY20131100798T patent/CY1114637T1/el unknown
2014
- 2014-05-14 US US14/277,095 patent/US20140315958A1/en not_active Abandoned
2018
- 2018-01-30 US US15/884,103 patent/US20180194730A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HN2009000499A (es)	2012-03-07
CY1114637T1 (el)	2016-10-05
CO6150132A2 (es)	2010-04-20
KR101418623B1 (ko)	2014-07-14
US20140315958A1 (en)	2014-10-23
CL2007002930A1 (es)	2008-04-04
MX2009002642A (es)	2009-05-28
HK1136287A1 (en)	2010-06-25
TWI428322B (zh)	2014-03-01
UY30633A1 (es)	2008-05-31
DK2097381T3 (da)	2013-09-23
IL197369A (en)	2015-06-30
CA2666170A1 (en)	2008-04-17
PT2097381E (pt)	2013-09-17
ZA200902469B (en)	2010-06-30
ES2427358T3 (es)	2013-10-30
SI2097381T1 (sl)	2013-11-29
WO2008043446A1 (en)	2008-04-17
JP5346293B2 (ja)	2013-11-20
IL197369A0 (en)	2009-12-24
JP2010505888A (ja)	2010-02-25
SV2009003187A (es)	2009-11-26
RU2009117388A (ru)	2010-11-20
CR10663A (es)	2009-07-31
BRPI0719828A2 (pt)	2014-02-04
CA2666170C (en)	2016-05-24
CN101547903A (zh)	2009-09-30
AU2007306716B2 (en)	2013-06-20
MA30878B1 (fr)	2009-11-02
TN2009000072A1 (en)	2010-08-19
KR20090061043A (ko)	2009-06-15
NZ576153A (en)	2012-02-24
JO3021B1 (ar)	2016-09-05
GT200900057A (es)	2009-12-09
AU2007306716A1 (en)	2008-04-17
PE20081459A1 (es)	2008-12-18
UA95984C2 (en)	2011-09-26
TW200831465A (en)	2008-08-01
RU2466992C2 (ru)	2012-11-20
AR062927A1 (es)	2008-12-17
US9957232B2 (en)	2018-05-01
SG175584A1 (en)	2011-11-28
US20180194730A1 (en)	2018-07-12
PA8750301A1 (es)	2009-01-23
MY152595A (en)	2014-10-31
EP2097381A1 (en)	2009-09-09
US20100173953A1 (en)	2010-07-08
CN101547903B (zh)	2014-01-15
EP2097381B1 (en)	2013-06-19
BRPI0719828B1 (pt)	2022-05-17

Publication	Publication Date	Title
PL2097381T3 (pl)	2013-11-29	Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu
PL1797037T3 (pl)	2015-07-31	Sposób otrzymywania 4-{4-[({[4-chloro-3-(trifluorometylo)-fenylo]amino}karbonylo)amino]fenoksy}-N-metylopirydyno-2-karboksyamidu
IL253119A0 (en)	2017-08-31	4-{4[({[4-chloro-3-(trifluoroacetyl)phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate and preparations including it
ZA200804030B (en)	2009-02-25	Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
ZA201101891B (en)	2012-05-30	The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
IL181169A0 (en)	2007-07-04	Trifluoromethyl substituted benzamides as kinase inhibitors
ZA200804057B (en)	2009-08-28	Herbicidal compositions based on 3-phenyluracils and N-[[4-[(cyclopropylamino)-carbonyl]phenyl]sulfonyl]-2-methoxybenzamide
ZA200801351B (en)	2009-09-30	Sulphonypyrrole hydrochloride salts as histone deacetylases inhibitors
BRPI0715725A2 (pt)	2013-09-17	cabeÇa de escova para uma escova de dentes, e, escova de dentes
SI2182949T1 (sl)	2013-10-30	(2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciklo(2.2.2)okt-3-il)benzofuran -2-karboksamid, nove oblike soli in postopki za njihovo uporabo
IL231463A0 (en)	2014-04-30	Carboxamide compounds and its use in the preparation of a medicine
EP1771441B8 (de)	2012-02-15	Neue carbonsäureamide als faktor xa-inhibitoren
IL225167A (en)	2016-03-31	Annotations (para-methoxy) phenyl-sulfonamide, n- (isobutyl), n - [(r2) - hydroxy- (r3) - benzyl-profile]
SG10201501749WA (en)	2015-05-28	Methods for administering long-lasting hypoglycemic agents
MX2010003989A (es)	2010-04-27	Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
ZA200604013B (en)	2007-08-29	Novel carboxamides for use as xa inhibitors
CL2007001691A1 (es)	2008-05-16	Metodo para hacer n-hidroxi-3-(4(((2-(2-metil-1h-indol-3-il)etil)amino)metil)fenil)-2e-2-propenamida.
AP2007004003A0 (en)	2007-06-30	N-[(3S)-pyrrolidin-3YL]-benzamide derivatives as monoamine re-uptake inhibitors
HK1101689A (en)	2007-10-26	Trifluoromethyl substituted benzamides as kinase inhibitors
IL210842A (en)	2016-05-31	A single solid product containing protein, protease inhibitor and salt of nac or nad and use of this preparation for oral administration of the protein
HK1130007A (en)	2009-12-18	Methods for administering long-lasting hypoglycemic agents